Paper36947394
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.
Pan B and 17 others. Drugs, 2023. Cited by 32 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials. Papers, record 36947394. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36947394
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sleep Initiation and Maintenance Disorders | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Antidepressive Agents | |
| Sleep |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06606938 | FMT for Insomnia Disorder (FMT-SLEEP) | Background |
Source ClinicalTrials.gov
References159
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,297,939 | A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone. | N Z Med J | 1992 | https://conductscience.org/library/papers/1297939 | PubMed |
| 2 | 21,120,125 | Sleep symptoms predict the development of the metabolic syndrome. | Sleep | 2010 | https://conductscience.org/library/papers/21120125 | PubMed |
| 3 | 10,674,059 | Meta-analysis of benzodiazepine use in the treatment of insomnia. | CMAJ | 2000 | https://conductscience.org/library/papers/10674059 | PubMed |
| 4 | 3,527,513 | Brotizolam, a triazolothienodiazepine, in insomnia. | Clin Pharmacol Ther | 1986 | https://conductscience.org/library/papers/3527513 | PubMed |
| 5 | 16,968,566 | A polysomnography study of eszopiclone in elderly patients with insomnia. | Curr Med Res Opin | 2006 | https://conductscience.org/library/papers/16968566 | PubMed |
| 6 | 17,702,264 | Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. | Sleep | 2007 | https://conductscience.org/library/papers/17702264 | PubMed |
| 7 | 19,584,739 | The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. | Int Clin Psychopharmacol | 2009 | https://conductscience.org/library/papers/19584739 | PubMed |
| 8 | 31,630,016 | Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. | Sleep Med Rev | 2019 | https://conductscience.org/library/papers/31630016 | PubMed |
| 9 | 15,701,215 | Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. | Curr Med Res Opin | 2004 | https://conductscience.org/library/papers/15701215 | PubMed |
| 10 | 20,191,935 | Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies. | J Clin Sleep Med | 2010 | https://conductscience.org/library/papers/20191935 | PubMed |
| 11 | 18,199,864 | Selective publication of antidepressant trials and its influence on apparent efficacy. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18199864 | PubMed |
| 12 | 34,902,823 | The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. | Sleep Med Rev | 2022 | https://conductscience.org/library/papers/34902823 | PubMed |
| 13 | 12,607,571 | Zolpidem "as needed" for the treatment of primary insomnia: a double-blind, placebo-controlled study. | Sleep Med Rev | 2002 | https://conductscience.org/library/papers/12607571 | PubMed |
| 14 | 22,465,450 | A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. | Sleep Med | 2012 | https://conductscience.org/library/papers/22465450 | PubMed |
| 15 | 8,071,269 | A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. | J Clin Psychiatry | 1994 | https://conductscience.org/library/papers/8071269 | PubMed |
| 16 | 16,477,959 | A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. | Sleep | 2005 | https://conductscience.org/library/papers/16477959 | PubMed |
| 17 | 21,966,075 | Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. | Sleep | 2011 | https://conductscience.org/library/papers/21966075 | PubMed |
| 18 | 24,680,372 | Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. | Lancet Neurol | 2014 | https://conductscience.org/library/papers/24680372 | PubMed |
| 19 | 11,471,853 | A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia. | J Int Med Res | 2001 | https://conductscience.org/library/papers/11471853 | PubMed |
| 20 | 19,413,143 | Insomnia with objective short sleep duration is associated with a high risk for hypertension. | Sleep | 2009 | https://conductscience.org/library/papers/19413143 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,955,666 | Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. | Drugs | 2026 | https://conductscience.org/library/papers/42955666 | PubMed |
| 42,889,895 | Exploring the Molecular Mechanism of Ganoderic Acid B for Insomnia Based on Metabolomics, Network Pharmacology, Molecular Docking, and Experimental Validation. | ACS Omega | 2026 | https://conductscience.org/library/papers/42889895 | PubMed |
| 42,856,849 | Comparative effectiveness of traditional Chinese medicine treatment strategies for insomnia: a systematic review and network meta-analysis. | Front Neurol | 2026 | https://conductscience.org/library/papers/42856849 | PubMed |
| 42,781,607 | Management of adult insomnia in Australia: a joint position statement of the Australasian Sleep Association, Sleep Health Foundation, Royal Australian College of General Practitioners, Australian Psychological Society, Pharmaceutical Society of Australia, and Australian Primary Health Care Nurses Association. | Sleep Adv | 2026 | https://conductscience.org/library/papers/42781607 | PubMed |
| 42,652,956 | Prunella vulgaris Compound Improves Sleep Architecture and Attenuates Hippocampal Injury in Insomnia Mice. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42652956 | PubMed |
| 42,499,498 | Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42499498 | PubMed |
| 41,883,496 | Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41883496 | PubMed |
| 41,483,206 | Pitfalls of insomnia management in the elderly: A narrative review. | Neurol Sci | 2026 | https://conductscience.org/library/papers/41483206 | PubMed |
| 40,434,499 | A new direction for adjunctive therapy of difficult-to-treat depression: examining the role of orexin receptor antagonists. | Eur Arch Psychiatry Clin Neurosci | 2025 | https://conductscience.org/library/papers/40434499 | PubMed |
| 40,230,824 | Inhalation aromatherapy for the treatment of comorbid insomnia: a systematic review and meta-analysis. | Front Psychiatry | 2025 | https://conductscience.org/library/papers/40230824 | PubMed |
| 40,143,154 | A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40143154 | PubMed |
| 40,092,087 | Efficacy and safety of idiopathic normal pressure hydrocephalus shunting: a systematic review and meta-analysis. | Am J Transl Res | 2025 | https://conductscience.org/library/papers/40092087 | PubMed |
| 39,815,642 | Determinants of Dropout From a Virtual Agent-Based App for Insomnia Management in a Self-Selected Sample of Users With Insomnia Symptoms: Longitudinal Study. | JMIR Ment Health | 2025 | https://conductscience.org/library/papers/39815642 | PubMed |
| 39,057,556 | Neurexan Prescription Is Associated with Lower Risk of Sleep Disorder Recurrence and Depression Prevalence as Compared to Z-Drugs and Benzodiazepines: A Retrospective Database Analysis in Germany. | Healthcare (Basel) | 2024 | https://conductscience.org/library/papers/39057556 | PubMed |
| 38,776,081 | Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models. | JAMA Netw Open | 2024 | https://conductscience.org/library/papers/38776081 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36947394
GET https://conductscience.org/api/papers/v1/36947394/references?page=2